Overview

The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

Status:
Not yet recruiting

Trial end date:
2025-09-15

Target enrollment:

Participant gender:

Summary

The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Randomized Controlled Study

Phase:

Phase 3

Details

Lead Sponsor:

Ruijin Hospital

Treatments:

Cyclophosphamide
Doxorubicin
Prednisone
Rituximab
Vincristine